CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,506 enrolled
Drug / intervention
Dabigatran etexilate +1 moredrug
Likely dose
Dabigatran etexilate 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02240667
NCT02240667N/ACompleted
CompareCT.gov

Drug Persistence/Adherence in Patients Being Treated With Dabigatran Etexilate or VKA for Stroke Prevention in Non-valvular Atrial Fibrillation (SPAF)

Boehringer Ingelheim·observational·Posted Sep 16, 2014·Updated Apr 19, 2019

In Brief

An observational study evaluating Dabigatran etexilate and Vitamin K antagonists for Atrial Fibrillation. Completed, enrolled 1,506 participants across 1 site.

Detailed Summary

1600 AF patients receiving Pradaxa or VKA for stroke prevention will be followed up for 12 months in quarterly visits. Prescriptions, adverse events and (if applicable) reasons for definitive treatment discontinuation will be collected. At 6 months, patient adherence will be assessed, using the Morisky Score.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 16, 2014
Enrollment StartSep 18, 2014
Primary CompletionDec 31, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 11.8 years ago

Interventions

Dabigatran etexilatedrug

150 mg or 110 mg capsules twice daily

Vitamin K antagonistsdrug

International Normalized Ratio (INR) 2-3